Bayer says guidance cut driven by Crop Science, Pharma
Reuters
Published Aug 08, 2023 06:48
Updated Aug 08, 2023 08:41
By Ludwig Burger
FRANKFURT (Reuters) -Bayer said on Tuesday that last month's cut to its full-year earnings target was mainly driven by a bleaker outlook at its Crop Science division and by expectations for flat pharmaceuticals sales.
The German drugs and pesticides maker said in unscheduled statement last month that it was projecting 2023 group earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-offs, to be in a range of 11.3 billion euros ($12.5 billion) and 11.8 billion euros on a currency-adjusted basis, down from 13.5 billion euros reported for 2022.
It specified in a statement on Tuesday that the adjusted EBITDA margin over 2023 sales at the agriculture business known as Crop Science would be about 21%, down from 25% projected in May.
Currency-adjusted divisional sales would be down by about 5% and not up by about 1.5% as previously seen.
CEO Bill Anderson, a former Roche executive, has had a challenging start since he took the top job in June. Bayer (ETR:BAYGN)'s main agriculture business has been hurt by cost inflation, dry weather weighing on farmers' demand, and by a slump in prices of glyphosate-based weedkillers from last year's highs when revenues were inflated by rivals' production outages.
Prescription drug sales would be flat and not up by about 1% as previously targeted, with the profit margin seen at about 28% this year, down from a previous goal of more than 29%.
Sales of non-prescription consumer health products, the smallest of Bayer's three divisions, were still seen up 5% this year.
Bayer also reported a net loss of 1.89 billion euros for the second quarter, weighed down by 2.3 billion euros in impairment charges.
It had previously cited preliminary figures as showing expected goodwill impairments worth about 2.5 billion euros, leading to a second-quarter net loss of 2 billion euros.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.